GlassScriptPhysician profile
Skylar Turner
NPI 1619550316
$2,073.63
in general payments reported to CMS, 2019-2025
23 companies · $1,451 in 2025
The $1,451 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $622 · 2025: $1,451.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,074.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,073.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $338.74 | 2024-2025 | |
| Novo Nordisk INC | $327.69 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $280.50 | 2024-2025 | Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $132.86 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $131.00 | 2024 | Jardiance |
| Insulet Corporation | $127.40 | 2024 | Omnipod |
| Pfizer INC. | $101.02 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $74.41 | 2024-2025 | Xifaxan |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $68.62 | 2024-2025 | Caplyta |
| Lilly USA, LLC | $66.45 | 2025 | Mounjaro, Zepbound, Jardiance |
| Sumitomo Pharma America, INC. | $64.80 | 2025 | Gemtesa |
| Amgen INC. | $64.04 | 2024-2025 | Repatha, Otezla, Otezla |
| Glaxosmithkline, LLC. | $50.68 | 2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Eisai INC. | $44.13 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $42.53 | 2025 | Rexulti |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $30.58 | 2024-2025 | Cologuard Collection Kit |
| Dexcom, INC. | $22.78 | 2024 | Dexcom G6 Transmitter |
| Viatris Specialty LLC | $21.60 | 2025 | Yupelri |
| Aimmune Therapeutics, INC. | $20.72 | 2025 | Zenpep |
| Phathom Pharmaceuticals, INC. | $17.30 | 2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $16.55 | 2025 | Trintellix |
| Verona Pharma, INC. | $16.11 | 2025 | Ohtuvayre |
| Novartis Pharmaceuticals Corporation | $13.12 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Skylar Turner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.